anti-BCMA CAR T-cell therapy (Editas Medicine/Bristol-Myers Squibb)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-BCMA CAR T-cell therapy (Editas Medicine/Bristol-Myers Squibb)
Drug Alias Nameanti-BCMA CAR T-cell therapy (Juno Therapeutics/Editas Medicine)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulators
TargetsTumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJuno Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEditas Medicine IncCelgene CorpBristol-Myers Squibb Company +[4] 
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A